Keeping you up to date on recent developments in oncology, including: SABR showing promise for spinal metastases; Chromosome amplification drives cancer progression via effects on secretion; IMRT shows well in study of upper-tract urothelial carcinoma
Matthew Ros, chief strategy and business officer for Epizyme Inc., said the company is “not providing specific guidance at the moment” about the sales force that will be deployed to market Tazverik (tazemetostat) in follicular lymphoma (FL), an indication for which U.S. regulators are considering the oral, first-in-class EZH2 inhibitor. “But I can assure you we’ve planned very thoughtfully” about the effort, he said. “That's always been a part of why we thought epithelioid sarcoma [ES] was such a strategically important component of the overall business strategy to get on-the-ground experience.” The sales force numbers 19 for now.
In the Dec. 20, 2019, issue of Science, Stefan Kaufmann, who is the founding director of the Max Planck Institute for Infection Biology, and his colleagues report that the immune system could calibrate its response to Pseudomonas aeruginosa by monitoring the bacterial quorum sensing chatter.